bkcui 发表于 2011-10-13 22:23 static/image/common/back.gif
2011ASCO
给个明确的翻译来！
本帖最后由 毕业 于 2011-10-14 00:12 编辑
bkcui 发表于 2011-10-13 22:57 static/image/common/back.gif
有人需要这个文献，因此贴出来。
总之，副作用偏大，继续研究的前景不是很好。
::L有点失望！
不过你这个是头颈癌啊，不是肺癌，我感觉如果是肺癌的话，如果效果很好，癌负荷减轻很多，那么病人的状态应该会有改观的，特别是那些剧烈的咳嗽，疼痛和颅压，改善的话总比那些副作用好些吧。
我还是很期待这个药物的，想弄点来试试。
易瑞沙与特罗凯耐药后，这个药的有效性如何？这点很关键
2012年第三届欧洲肺癌大会
议题1 新的TKI药物：Docomitinib
研究1：来自英国F.Blackhall医生
英国F.Blackhall医生报告了Dacomitinib(PF-00299804) 在NSCLC中的疗效及二、三线治疗与厄洛替尼的对比研究。
Dacomitinib是作用于HER-1/EGFR、HER-2及HER-4不可逆的TK抑制剂；两项Ⅱ期研究评价了Dacomitinib单药：用于1个以上的化疗方案及厄洛替尼治疗失败的KRAS野生型NSCLC患者；1个或2个化疗方案失败的晚期NSCLC患者；2项研究均包括非肺腺癌患者。
该研究得出的结论认为，BR.21研究结果厄洛替尼与安慰剂对比二线或三线治疗NSCLC，中位无进展生存及OS分别为2.2个月和6.7个月；Dacomitinib治疗化疗或厄洛替尼耐药非腺癌的中位无进展生存期及总生存期分别为11.1周(2.6 个月)、26.2周(6.1个月)；Dacomitinib与厄洛替尼治疗二线或三线治疗NSCLC非腺癌的中位无进展生存期相似(8.7周 vs. 8.0周)，然而生存曲线分离；D要高于E(HR为0.64)，有35%的改善；
Dacomitinib作用于不同组织类型的Ⅲ期研究中正在进行的有BR.26研究：Dacomitinib与安慰剂治疗耐药的NSCLC；ARCHER 1009研究：Dacomitinib与厄洛替尼对比。
研究2：来自瑞士Pfizer AG教授
瑞士Pfizer AG教授报告了Dacomitinib与厄洛替尼治疗化疗失败的进展期NSCLC患者 Ⅱ期的随机临床试验。
该试验的研究结果显示Dacomitinib与厄洛替尼相比可以延长无进展生存期；Dacomitini主要控制NSCLC患者的临床症状，提高了生活质量。
此研究结果为以后的HRQoL试验提供强有力的理论依据：全球的Ⅲ期临床研究ARCHER 1009以及最近Dacomitinib与厄洛替尼比较二线或三线治疗NSCLC的疗效评价等研究均应用这些指标。
发现国内已有YL，本坛关注并不多，何因？
个人觉得这个药和2992差不多的，都是不可逆的HER，EGFR抑制剂
目前的靶点都集中在HER1、HER2，不知是否存在交叉耐药。
本帖最后由 lostm 于 2012-10-21 21:41 编辑
我查到了最新进展。
无进展期相对特罗凯明显增强。2.86 versus 1.91 months
但副作用更大。需要减量的，dacomitinib对特，41% 对 17%
http://www.news-medical.net/news/20120808/Progression-free-NSCLC-survival-boosted-by-dacomitinib.aspx
Progression-free NSCLC survival boosted by dacomitinib
Published on August 8, 2012 at 5:15 PM · No Comments
Tweet inShare0By Liam Davenport
In patients with non-small-cell lunch cancer (NSCLC), dacomitinib confers a significant progression-free survival (PFS) benefit over erlotinib across a range of clinical and molecular subgroups, the results of an international study indicate.
The reversible tyrosine kinase inhibitors erlotinib and gefitinib target single members of the human epidermal growth factor receptor (HER/EGFR) family, and have shown effectiveness in the first-line treatment of NSCLC with EGFR-sensitizing mutations.
Noting that dacomitinib is an irreversible pan-HER inhibitor, Suresh Ramalingam, from Emory University, in Atlanta, Georgia, USA, and colleagues randomly assigned 189 patients with NSCLC to receive either dacomitinib 45 mg or erlotinib 150 mg once daily.
All NSCLC patients had an Eastern Cooperative Oncology Group performance status of 0 to 2, no prior HER-directed therapy, and had received up to two prior chemotherapy regimens.
The results, published in the Journal of Clinical Oncology, indicate that median PFS was significantly greater with dacomitinib than erlotinib, at 2.86 versus 1.91 months (hazard ratio =0.66). The mean duration of response was 16.56 months for dacomitinib and 9.23 months for erlotinib.
Dividing the patients by tumor type, the team found that median PFS was 3.71 months with dacomitinib and 1.91 with erlotinib in patients with KRAS wild-type tumors (HR=0.55), and 2.21 months and 1.68 months, respectively, in patients with KRAS wild-type/EGFR wild-type tumors (HR= 0.61).
There was no significant difference in median overall survival between the two treatment groups, at 9.53 months in patients treated with dacomitinib and 7.44 months in those given erlotinib.
Treatment-related adverse events were more frequent in dacomitinib-treated patients than in those given erlotinib, most commonly grade 1 and 2 skin and gastrointestinal events. Treatment-related dose reductions were required in 40.9% and 17.0% of patients, respectively.
"The results documented here for dacomitinib suggest that irreversible pan-HER inhibition may offer a new treatment option for patients with advanced NSCLC, potentially representing an effective alternative to reversible inhibition of EGFR," the researchers conclude.
Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.
1f49b356-b7db-4ea6-a290-4e2572675213|0|.0
seacat 发表于 2012-10-4 21:41 static/image/common/back.gif
目前的靶点都集中在HER1、HER2，不知是否存在交叉耐药。
也想了解一下。